Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.